Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Mar 10;322(7286):579-82.
doi: 10.1136/bmj.322.7286.579.

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

U Eriksson  1 , B Seifert, A Schaffner
Affiliations
Clinical Trial

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

U Eriksson et al. BMJ. .

Abstract

Objective: To test the hypothesis that amphotericin B deoxycholate is less toxic when given by continuous infusion than by conventional rapid infusion.

Design: Randomised, controlled, non-blinded, single centre study.

Setting: University hospital providing tertiary clinical care.

Patients: 80 mostly neutropenic patients with refractory fever and suspected or proved invasive fungal infections.

Intervention: Patients were randomised to receive 0.97 mg/kg amphotericin B by continuous infusion over 24 hours or 0.95 mg/kg by rapid infusion over four hours.

Main outcome measures: Patients were evaluated for side effects related to infusion, nephrotoxicity, and mortality up to three months after treatment. Analysis was on an intention to treat basis.

Results: Patients in the continuous infusion group had fewer side effects and significantly reduced nephrotoxicity than those in the rapid infusion group. Overall mortality was higher during treatment and after three months' follow up in the rapid infusion than in the continuous infusion group.

Conclusion: Continuous infusions of amphotericin B reduce nephrotoxicity and side effects related to infusion without increasing mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Percentage of patients with fever during first days of treatment with amphotericin B
Figure 3
Figure 3
C reactive protein (CRP) concentrations during treatment with amphotericin B compared with baseline levels, expressed as median of ΔCRP (ΔCRP=CRP−CRPbaseline) in mg/l
See this image and copyright information in PMC

References

    1. Ellis ME, Al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother. 1992;36:172–179. - PMC - PubMed
    1. Chabot GG, Pazdur R, Valeriote FA, Baker LH. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci. 1989;78:307–310. - PubMed
    1. Oldfield EC, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother. 1990;34:1402–1408. - PMC - PubMed
    1. Cruz AM, Peacock JE, Loomer L, Holder LH, Evans GW, Powell BL, et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med. 1992;93:123–130. - PubMed
    1. Millis W, LiChopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single center experience of 133 episodes in 116 patients. Br J Haematol. 1994;86:754–760. - PubMed

MeSH terms